|Articles|February 15, 2002

BioPharm International

  • BioPharm International-02-01-2002
  • Volume 15
  • Issue 2

The Immunogenicity of Therapeutic Proteins

By Fiona Adair and Daniel Ozanne,Biovation Ltd., pp. 30-36. Immunogenicity is often a barrier to further development of potentially therapeutic proteins. That barrier often remains unknown until late in the development chain. The authors explore various strategies for preventing immunogenicity and for predicting it earlier in the process.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 24 years ago

Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection

almost 24 years ago

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

almost 24 years ago

Outsourcing Outlook: Reaping the Benefits of E-Procurement

almost 24 years ago

Analytical Advances: Calibration Management of Outsourced Calibrations

almost 24 years ago

High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge

almost 24 years ago

Inside Washington: Costs and Controls Challenge Manufacturers

almost 24 years ago

21 CFR Part 11: (Un)Expected Added Value

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!